| Literature DB >> 22126605 |
Shrinivas Bishu1, Violeta Arsenescu, Eun Y Lee, H David Vargas, Willem J S de Villiers, Razvan Arsenescu.
Abstract
BACKGROUND: Adult onset autoimmune enteropathy (AIE) is a rare condition characterized by diarrhea refractory to dietary therapy diagnosed in patients with evidence of autoimmune conditions. Auto-antibodies to gut epithelial cells and other tissues are commonly demonstrated. Despite increasing awareness, the pathogenesis, histologic, immunologic and clinical features of AIE remain uncertain. There remains controversy regarding the diagnostic criteria, the frequency and types of auto-antibodies and associated autoimmune conditions, and the extent and types of histologic and immunologic abnormalities. CD4+ T-cells are thought to at least responsible for this condition; whether other cell types, including B- and other T-cell subsets are involved, are uncertain. We present a unique case of AIE associated with a CD8+CD7- lymphocytosis and review the literature to characterize the histologic and immunologic abnormalities, and the autoantibodies and autoimmune conditions associated with AIE. CASEEntities:
Mesh:
Substances:
Year: 2011 PMID: 22126605 PMCID: PMC3287162 DOI: 10.1186/1471-230X-11-131
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Liver function test and histologic features pre- and post-prednisone
| Pre-prednisone | Post-prednisone | |||
|---|---|---|---|---|
| Presentation | 15 months | 21 months | 26 months | |
| Liver Function Tests | ||||
| AST (U/L) | 107 | 43 | 41 | 65 |
| ALT (U/L) | 95 | 46 | 97 | 82 |
| ALP (U/L) | 240 | 205 | 110 | 123 |
| Albumin (g/dL) | 2.2 | 1.5 | 2.1 | 3.5 |
| Histology | ||||
| Histology | IEL | Intact villi | IEL | IEL |
| Immuno-phenotype | not obtained | Jejunum + illeum: | Jejunum: | Jejunum: |
Figure 1Duodenal biopsy at presentation demonstrating regions of IEL (large arrow) with normal appearing LP (small arrow) and interspersed areas of villous blunting (*).
Figure 2Duodenal biopsy before steroid therapy demonstrating regions with persistent IEL (large arrow) with marked LP lymphocytosis (small arrow).
Figure 3Duodenal biopsy 4 weeks after completing steroid therapy obtained during symptom resolution demonstrating normal tissue (IEL and LP compartments marked by large and small arrows, respectively).
Figure 4Duodenal biopsy obtained at the same time as in figure 3, but from a different region demonstrating abnormal tissue with blunted architecture (IEL and LP compartments marked by large and small arrows, respectively).
Reported Cases and Auto-Antibodies
| Reference | Gender, Age | Anti-Enterocyte antibodies | Anti- | Auto-antibodies | Auto-immune involvement | Immune abnormalities |
|---|---|---|---|---|---|---|
| 16 | F, 38 | IgA and IgG | NR | - | NR | NR |
| 16 | F, 47 | IgA and IgG | NR | Anti-actin | NR | NR |
| 8 | F, 39 | + | NR | Anti-thyroid microsomal Anti-thyroglobulin | ITP | Impaired antibody production to mitogens and protein antigens |
| 19 | F, 50 | IgG | NR | - | Perivisceritis | NR |
| 18 | F, 82 | IgG | NR | NR | NR | NR |
| 20 | M, 67 | NR | NR | NR | NR | NR |
| 20 | F, 39 | NR | NR | NR | NR | NR |
| 22 | F, 58 | - | NR | Anti-parietal cell | T- and B-cell pulmonary infiltrate | CD4+ lymphopenia |
| 15 | M, 54 | + | NR | pANCA | NR | NR |
| 3 | M, 19 | - | IgG | NR | Collagenous enterocolitis | NR |
| 17 | F, 35 | IgA and IgG | NR | Anti-CCP | Rheumatoid arthritis | NR |
| 21 | M, 59 | NR | NR | Anti-intrinsic factor | Pangastritis (atrophic) | NR |
| 4 | M, 21 | NR | NR | RF | Autoimmune hemolytic anemia | Elevated IgG |
| 24 | M, 58 | + | NR | Anti-parietal cell | NR | NR |
| 23 | M, 37 | IgG | - | ANA | Pancreatic insufficiency | NR |
| 23 | M, 75 | IgG | IgG | Anti-acetylcholine receptor | Myasthenia gravis | NR |
| 23 | F, 46 | - | IgG | - | Psoriatic arthritis | NR |
| 23 | F, 42 | - | IgG | - | Atopic dermatitis | NR |
| 23 | F, 38 | - | IgG | Anti-parietal cell | Pancreatic insufficiency | NR |
| 23 | F, 76 | IgG | - | ANA | NR | hypogammaglobulinemia (low IgG and low IgM) |
| 23 | M, 55 | - | - | - | NR | CVID |
| 23 | M, 40 | IgM | - | ANA | NR | CVID |
| 23 | M, 54 | - | IgG | - | NR | CVID |
| 23 | M, 67 | IgA and IgG | - | - | NR | Polyclonal hypergammaglobulinemia |
| 23 | F, 45 | IgG | IgG | Anti-SSA | Sjogren's | NR |
| 23 | M, 59 | IgG | - | ANA | Autoimmune gastroenterocolitis | NR |
| 23 | M, 75 | NR | NR | Anti-saccharomyces cerevisiae antibodies | Autoimmune gastroenterocolotis | Polyclonal hypergammaglobulinemia |
| 23 | F, 61 | IgG | - | pANCA | Hypothyroidism | NR |
| 23 | F, 59 | IgG | - | ANA | Lymphocytic colitis | NR |
Abbreviations:
ANA: anti-nuclear antibody
ANCA: anti-neutrophil cytoplasmic antibody (p: protoplasmic)
Anti-CCP: anti-cyclic citrullinated peptide antibody
CVID: common variable immune deficiency
ITP: idiopathic thrombocytopenic purpura
RF: rheumatoid factor
NR: not reported
Reported Cases with Sites of Disease and Histologic Findings
| Reference | Gender, Age | Involved sites | Intra-epithelial | Lamina propria |
|---|---|---|---|---|
| 16 | F, 38 | Small intestine | 46%a | NR |
| 16 | F, 47 | Small intestine | 42%a | NR |
| 8 | F, 39 | Stomach, duodenum, jejunum, colon, recto-sigmoid | 12%a (normal), decreased CD3- CD103+, aberrant CD3+CD4+CD103-, increased HLA-II expression on CD3+ | Lympho-plasmacytic infiltrate (CD3+) |
| 19 | F, 50 | Duodenum, colon | Duodenum: | Colon: |
| 18 | F, 82 | Duodenum | Lympho-plasmacytic infiltrate | NR |
| 20 | M, 67 | colon | NR | NR |
| 20 | F, 39 | Small intestine, colon | NR | NR |
| 22 | F, 58 | Stomach, duodenum, jejunum, colon, rectosigmoid | Duodenum: | Duodenum: |
| 15 | M, 54 | Duodenum, ileum | Duodenum: | NR |
| 3 | M, 19 | Duodenum, ileum, colon | Normal | NR |
| 17 | F, 35 | Duodenum | IEL = > 40/100 | NR |
| 21 | M, 59 | Stomach, colon, ileum | Normal | Colon + Ileum: |
| 4 | M, 21 | Duodenum | IEL = 50/100 | CD4+ preponderance, occasional CD8+ and neutrophils, rare CD20+ |
| 24 | M, 58 | Duodenum, ileum, colon | Lymphocytosis | Lympho-plasmacytic infiltrate |
Abbreviations:
IEL: Intra-epithelial lymphocytosis
a: expressed as a percentage of total cells